Journal articlePreclinical

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 Apr. Alam F, Gaspari TA, Kemp-Harper BK and 10 others.

Study type

Journal article

Subjects

Animal / preclinical (no Humans MeSH term)

Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published

2023 Apr

PubMed

PMID 36753958 ↗

DOI

10.1016/j.biopha.2023.114370 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

B7-33 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

MiceAnimalsMalePerindoprilRelaxinMicrovascular RarefactionCardiomyopathiesModels, TheoreticalInflammationHypertrophy

Other papers on B7-33

Randomized controlled trial · 2025

End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)

Review · 2024

Relaxin agonists under preclinical and early clinical investigation for the treatment of heart failure

Journal article · 2016

A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page